...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.
【24h】

Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates.

机译:新型地昔洛芬四乙酰核黄素缀合物的合成和生物活性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A series of novel dexibuprofen derivatives covalently linked via alkylene spacers of variable length to tetraacetylated riboflavin have been developed. The target compounds became accessible by reaction of the chloromethyl ester of dexibuprofen with tetraacetylriboflavin (compound 7) or by synthesis of the appropriate N3-(omega-iodoalkyl)-2',3',4',5'-Tetraacetylriboflavin followed by treatment with dexibuprofen (derivatives 8-11), respectively. Biological screening revealed that the target compounds exhibit antiproliferative effects on MCF-7 breast cancer and HT-29 colon carcinoma cells with IC50 values in the range of 8-15 microM. Enzymatic studies on human platelets indicated significant COX-1 inhibitory activities of the target compounds.
机译:已经开发了一系列通过可变长度的亚烷基间隔基与四乙酰化核黄素共价连接的新型地昔洛芬衍生物。通过地昔布洛芬的氯甲基酯与四乙酰基核黄素(化合物7)反应或通过合成适当的N3-(ω-碘烷基)-2',3',4',5'-四乙酰基核黄素,然后用四氢呋喃处理,可以得到目标化合物。地昔布洛芬(衍生物8-11)。生物筛选显示,目标化合物对MCF-7乳腺癌和HT-29结肠癌细胞具有抗增殖作用,IC50值在8-15 microM之间。对人血小板的酶研究表明目标化合物具有显着的COX-1抑制活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号